US FDA Puts Mirati’s KRAS Challenge To Amgen In The Slow Lane

Regulator's Decision Slated For December 2022

 
• By Ayisha Sharma
  
Chess pieces in different lanes, symbolizing a race,
While Amgen Won The Race To Launch, Mirati Claims Its Candidate Could Be Best In Class • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category